This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Intradigm Corporation. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Innovations in Cancer Treatment by Quinn Q Tang
Introduction
Quinn Q Tang is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of cancer treatment through his innovative research and patent.
Latest Patents
Quinn Q Tang holds 1 patent titled "Targets for tumor growth inhibition." This invention relates to methods for treating cancers by manipulating target gene expression. The methods involve up-regulation, silencing, and/or down-regulation of genes such as EGFR-RP, TRA1, MFGE8, TNFSF13, and ZFP236. These methods are useful in treating cancers and inhibiting tumor growth by enhancing the expression of validated target genes like ICT1030 for various therapeutic modalities. Additionally, RNA interference techniques are employed to silence and down-regulate targets such as ICT1024, ICT1025, ICT1031, and ICB1003, which are validated for antibody and small molecule drug modalities.
Career Highlights
Quinn Q Tang is currently associated with Intradigm Corporation, where he continues to advance his research in cancer therapies. His work focuses on innovative approaches to gene therapy and targeted treatments.
Collaborations
Quinn collaborates with esteemed colleagues, including Patrick Y Lu and Frank Y Xie, to further enhance the impact of his research in the field of oncology.
Conclusion
Quinn Q Tang's contributions to cancer treatment through his innovative patent demonstrate his commitment to advancing medical science. His work has the potential to significantly improve therapeutic options for cancer patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile